Enteropathogenic and enterohemorrhagic Escherichia coli infections: Emerging themes in pathogenesis and prevention

Canadian Journal of Gastroenterology

Volumn 16, Issue 11, 2002, Pages 771-778

  Vallance, Bruce A ^a   Chan, Crystal ^a   Robertson, Marilyn L ^a   Finlay, B Brett ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Citrobacter; Diarrhea; EHEC; EPEC; Escherichia coli; Hemolytic uremic syndrome; Infection; Pathogenicity island; Rodentium

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; ESCHERICHIA COLI VACCINE; VIRULENCE FACTOR;

ARTICLE; BACTERIAL VIRULENCE; CHILD HEALTH; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIARRHEA; DISEASE TRANSMISSION; DRUG TARGETING; ENTEROBACTER INFECTION; EPIDEMIC; ESCHERICHIA COLI; GASTROINTESTINAL HEMORRHAGE; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; HOST CELL; HUMAN; INFECTION RATE; NONHUMAN; NORTH AMERICA; PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; VACCINATION;

EID: 0036869942     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2002/410980     Document Type: Article

References (55)

1. Finlay BB, Cossart P. Exploitation of mammalian host cell functions by bacterial pathogens. Science 1997;276:718-25.
2. Vallance BA, Finlay BB. Exploitation of host cells by enteropathogenic Escherichia coli. Proc Natl Acad Sci USA 2000;97:8799-806.
3. Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998;11:142-201.
4. Frankel G, Phillips AD, Rosenshine I, Dougan G, Kaper JB, Knutton S. Enteropathogenic and enterohaemorrhagic Escherichia coli: more subversive elements. Mol Microbiol 1998;30:911-21.
5. Goosney DL, Gruenheid S, Finlay BB. Gut feelings: enteropathogenic E coli (EPEC) interactions with the host. Annu Rev Cell Dev Biol 2000;16:173-89.
6. Hill SM, Phillips AD, Walker-Smith JA. Enteropathogenic Escherichia coli and life threatening chronic diarrhoea. Gut 1991;32:154-8.
7. Fagundes-Neto U, Kallas MR, Patricio FR. Morphometric study of the small bowel mucosa in infants with diarrhea due to enteropathogenic Escherichia coli strains. Hepatogastroenterology 1997;44:1051-6.
8. Griffin PM, Ostroff S, Tauxe RV, et al. Illnesses associated with Escherichia coli O157:H7 infections. A broad clinical spectrum. Ann Intern Med 1988;109:705-712.
9. Karch H. The role of virulence factors in enterohemorrhagic Escherichia coli (EHEC)-associated hemolytic-uremic syndrome. Semin Thromb Hemost 2001;27:207-13.
10. DeVinney R, Gauthier A, Abe A, Finlay BB. Enteropathogenic Escherichia coli: a pathogen that inserts its own receptor into host cells. Cell Mol Life Sci 1999;55:961-76.
11. Abe A, Heczko U, Hegele RG, Finlay BB. Two enteropathogenic Escherichia coli type III secreted proteins, EspA and EspB, are virulence factors. J Exp Med 1998;188:1907-16.
12. Marches O, Nougayrede JP, Boullier S, et al. Role of tir and intimin in the virulence of rabbit enteropathogenic Escherichia coli serotype O103:H2. Infect Immun 2000;68:2171-82.
13. Elliott SJ, Wainwright LA, McDaniel TK, et al. The complete sequence of the locus of enterocyte effacement (LEE) from enteropathogenic Escherichia coli E2348/69. Mol Microbiol 1998;28:1-4.
14. Abe A, Nagano H. Functional analysis of the type III secretion system in enteropathogenic Escherichia coli O157:H45. Microbiol Immunol 2000;44:857-61.
15. Kenny B. Mechanism of action of EPEC type III effector molecules. Int J Med Microbiol 2002;291:469-77.
16. Tauschek M, Strugnell RA, Robins-Browne RM. Characterization and evidence of mobilization of the LEE pathogenicity island of rabbit-specific strains of enteropathogenic Escherichia coli. Mol Microbiol 2002;44:1533-50.
17. Deng W, Li Y, Vallance BA, Finlay BB. Locus of enterocyte effacement from Citrobacter rodentium: sequence analysis and evidence for horizontal transfer among attaching and effacing pathogens. Infect Immun 2001;69:6323-35.
18. McDaniel TK, Kaper JB. A cloned pathogenicity island from enteropathogenic Escherichia coli confers the attaching and effacing phenotype on E. coli K-12. Mol Microbiol 1997;23:399-407.
19. Jarvis KG, Giron JA, Jerse AE, McDaniel TY, Donnenberg MS, Kaper JB. Enteropathogenic Escherichia coli contains a putative type III secretion system necessary for the export of proteins involved in attaching and effacing lesion formation. Proc Natl Acad Sci USA 1995;92:7996-8000.
20. Michiels T, Wattiau P, Brasseur R, Ruysschaert JM, Cornelis G. Secretion of Yop proteins by Yersiniae. Infect Immun 1990;58:2840-9.
21. Sekiya K, Ohishi M, Ogino T, Tamano K, Sasakawa C, Abe A. Supermolecular structure of the enteropathogenic Escherichia coli type III secretion system and its direct interaction with the EspA-sheath-like structure. Proc Natl Acad Sci USA 2001;98:11638-43.
22. Wilson RK, Shaw RK, Daniell S, Knutton S, Frankel G. Role of EscF, a putative needle complex protein, in the type III protein translocation system of enteropathogenic Escherichia coli. Cell Microbiol 2001;3:753-62.
23. Luo Y, Bertero MG, Frey EA, et al. Structural and biochemical characterization of the type III secretion chaperones CesT and SigE. Nat Struct Biol 2001;8:1031-6.
24. Kenny B, DeVinney R, Stein M, Reinscheid DJ, Frey EA, Finlay BB. Enteropathogenic E. coli (EPEC) transfers its receptor for intimate adherence into mammalian cells. Cell 1997;91:511-20.
25. Kenny B, Jepson M. Targeting of an enteropathogenic Escherichia coli (EPEC) effector protein to host mitochondria. Cell Microbiol 2000;2:579-90.
26. Elliott SJ, Krejany EO, Mellies JL, Robins-Browne RM, Sasakawa C, Kaper JB. EspG, a novel type III system-secreted protein from enteropathogenic Escherichia coli with similarities to VirA of Shigella flexneri. Infect Immun 2001;69:4027-33.
27. Weinrauch Y, Drujan D, Shapiro SD, Weiss J, Zychlinsky A. Neutrophil elastase targets virulence factors of enterobacteria. Nature 2002;417:91-4.
28. DeVinney R, Stein M, Reinscheid D, Abe A, Ruschkowski S, Finlay BB. Enterohemorrhagic Escherichia coli O157:H7 produces Tir, which is translocated to the host cell membrane but is not tyrosine phosphorylated. Infect Immun 1999;67:2389-98.
29. Kenny B, Lai LC, Finlay BB, Donnenberg MS. EspA, a protein secreted by enteropathogenic Escherichia coli, is required to induce signals in epithelial cells. Mol Microbiol 1996;20:313-23.
30. McNamara BP, Koutsouris A, O'Connell CB, Nougayrede JP, Donnenberg MS, Hecht G. Translocated EspF protein from enteropathogenic Escherichia coli disrupts host intestinal barrier function. J Clin Invest 2001;107:621-9.
31. Crane JK, McNamara BP, Donnenberg MS. Role of EspF in host cell death induced by enteropathogenic Escherichia coli. Cell Microbiol 2001;3:197-211.
32. Kenny B, Ellis S, Leard AD, Warawa J, Mellor H, Jepson MA. Co-ordinate regulation of distinct host cell signalling pathways by multifunctional enteropathogenic Escherichia coli effector molecules. Mol Microbiol 2002;44:1095-107.
33. Yoshida S, Katayama. E, Kuwae A, Mimuro H, Suzuki T, Sasakawa C. Shigella deliver an effector protein to trigger host microtubule destabilization, which promotes Rac1 activity and efficient bacterial internalization. EMBO J 2002;21:2923-35.
34. Goosney DL, DeVinney R, Pfuetzner RA, Frey EA, Strynadka NC, Finlay BB. Enteropathogenic E. coli translocated intimin receptor, Tir, interacts directly with alpha-actinin. Curr Biol 2000;10:735-8.
35. Gruenheid S, DeVinney R, Bladt F, et al. Enteropathogenic E. coli Tir binds Nck to initiate actin pedestal formation in host cells. Nat Cell Biol 2001;3:856-9.
36. Goosney DL, DeVinney R, Finlay BB. Recruitment of cytoskeletal and signaling proteins to enteropathogenic and enterohemorrhagic Escherichia coli pedestals. Infect Immun 2001;69:3315-22.
37. Kalman D, Weiner OD, Goosney DL, et al. Enteropathogenic E. coli acts through WASP and Arp2/3 complex to form actin pedestals. Nat Cell Biol 1999;1:389-91.
38. DeVinney R, Puente JL, Gauthier A, Goosney D, Finlay BB. Enterohaemorrhagic and enteropathogenic Escherichia coli use a different Tir-based mechanism for pedestal formation. Mol Microbiol 2001;41:1445-58.
39. Kenny B. The enterohaemorrhagic Escherichia coli (serotype O157:H7) Tir molecule is not functionally interchangeable for its enteropathogenic E. coli (serotype O127:H6) homologue. Cell Microbiol 2001;3:499-510.
40. Abe A, Kenny B, Stein M, Finlay BB. Characterization of two virulence proteins secreted by rabbit enteropathogenic Escherichia coli, EspA and EspB, whose maximal expression is sensitive to host body temperature. Infect Immun 1997;65:3547-55.
41. Vallance BA, Deng W, Knodler LA, Finlay BB. Mice lacking T and B lymphocytes develop transient colitis and crypt hyperplasia yet suffer impaired bacterial clearance during Citrobacter rodentium infection. Infect Immun 2002;70:2070-81.
42. Luperchio SA, Newman JV, Dangler CA, et al. Citrobacter rodentium, the causative agent of transmissible murine colonic hyperplasia, exhibits clonality: synonymy of C. rodentium and mouse-pathogenic Escherichia coli. J Clin Microbiol 2000;38:4343-50.
43. Higgins LM, Frankel G, Douce G, Dougan G, MacDonald TT. Citrobacter rodentium infection in mice elicits a mucosal Th1 cytokine response and lesions similar to those in murine inflammatory bowel disease. Infect Immun 1999;67:3031-9.
44. Higgins LM, Frankel G, Connerton I, Goncalves NS, Dougan G, MacDonald TT. Role of bacterial intimin in colonic hyperplasia and inflammation. Science 1999;285:588-91.
45. Simmons CP, Clare S, Dougan G. Understanding mucosal responsiveness: lessons from enteric bacterial pathogens. Semin Immunol 2001;13:201-9.
46. Elewaut D, DiDonato JA, Kim JM, Truong F, Eckmann L, Kagnoff MF. NF-kB is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria. J Immunol 1999;163:1457-66.
47. Simmons CP, Goncalves NS, Ghaem-Maghami M, et al. Impaired resistance and enhanced pathology during infection with a noninvasive, attaching-effacing enteric bacterial pathogen, Citrobacter rodentium, in mice lacking IL-12 or IFN-γ. J Immunol 2002;168:1804-12.
48. Li Y, Frey E, Mackenzie AM, Finlay BB. Human response to Escherichia coli O157:H7 infection: antibodies to secreted virulence factors. Infect Immun 2000;68:5090-5.
49. Blank TE, Zhong H, Bell AL, Whittam TS, Donnenberg MS. Molecular variation among type IV pilin (bfpA) genes from diverse enteropathogenic Escherichia coli strains. Infect Immun 2000;68:7028-38.
50. Quintana Flores VM, Campos de Souza Fernandes RC, Sousa de Macedo Z, Medina-Acosta E. Expression and purification of the recombinant enteropathogenic Escherichia coli vaccine candidates BfpA and EspB. Protein Expr Purif 2002;25:16-22.
51. Collins SM, Vallance B, Barbara G, Borgaonkar M. Putative inflammatory and immunological mechanisms in functional bowel disorders. Best Pract Res Clin Gastroenterol 1999;13:429-36.
52. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778-83.
53. Collins SM, Piche T, Rampal P. The putative role of inflammation in the irritable bowel syndrome. Gut 2001;49:743-5.
54. Sartor RB. Review article: Role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. Aliment Pharmacol Ther 1997;11(Suppl 3):17-22.
55. Guihot G, Guimbaud R, Bertrand V, et al. Inducible nitric oxide synthase activity in colon biopsies from inflammatory areas: correlation with inflammation intensity in patients with ulcerative colitis but not with Crohn's disease. Amino Acids 2000;18:229-37.